Working... Menu

Safety and Efficacy Assessments of Osalmid in Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03670173
Recruitment Status : Recruiting
First Posted : September 13, 2018
Last Update Posted : April 9, 2019
Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Information provided by (Responsible Party):
Jumei Shi, Shanghai 10th People's Hospital

Brief Summary:
This study aims to evaluate the safety and efficacy of a traditional cholagogue drug osalmid, 2-hydroxy-N-(4-hydroxyphenyl)-benzamide, in the treatment of multiple myeloma (MM).

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: Osalmid Phase 1 Phase 2

Detailed Description:
Osalmid, 2-hydroxy-N-(4-hydroxyphenyl)-benzamide, is a traditional cholagogue and is clinically used in China to promote biliary drainage and protect liver function. Studies have shown that osalmid is an inhibitor of ribonucleotide reductase (RR). Recently, it was proven by our group that osalmid induced a dose-dependent lethality in multiple myeloma (MM) cell lines H929, OPM2, U266, OCI-MY5, and RPMI 8266, as well as in MM xenograft mouse models. This study aims to assess the safety and efficacy of osalmid in the treatment of MM.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Intervention Model Description: multi-center, single-arm, open-label, non-blind
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Efficacy Assessments of Osalmid in the Treatment of Multiple Myeloma
Actual Study Start Date : October 1, 2018
Estimated Primary Completion Date : January 31, 2020
Estimated Study Completion Date : September 30, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Arm Intervention/treatment
Experimental: Osalmid
Participants are initially given oral capsules with 0.5g tid osalmid daily for two weeks. Thereafter, the dosage will be increased by 0.25g tid every two weeks as tolerated by participants to a maximum daily dosage of 1.0g tid for up to one year. One course of osalmid treatment lasts four weeks. Response will be assessed at the end of each treatment course, and patients who have achieved MR (minor remission) or more than MR at the end of the fourth course will continue to take 1.0g tid osalmid daily for consolidation / maintenance therapy. Otherwise, patients who have not achieved MR at the end of the fourth course and patients who are assessed for PD (progression of disease) at the end of each course will receive salvage treatment, such as a combined treatment of osalmid and dexamethasone or the VCD (bortezomib, cyclophosphamide and dexamethasone) regimen.
Drug: Osalmid
Participants are initially given oral capsules with 0.5g tid osalmid daily for two weeks. Thereafter, the dosage will be increased by 0.25g tid every two weeks as tolerated by participants to a maximum daily dosage of 1.0g tid for up to one year.
Other Name: 2-hydroxy-N-(4-hydroxyphenyl)-benzamide

Primary Outcome Measures :
  1. overall response rate [ Time Frame: at week16 ]
    M protein qualification in serum and/or urine decline of at least 25%, 50%, 75%, or 90%

Secondary Outcome Measures :
  1. time to progression [ Time Frame: at week 48 ]
    from the start of therapy to disease progression

  2. duration of response [ Time Frame: at week 48 ]
    from the time response was achieved to disease progression or death

  3. progression-free survival [ Time Frame: at week 48 ]
    from study entry to disease progression or death

  4. overall survival [ Time Frame: at week 48 ]
    from the date of study entry to the date of death or last follow-up

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients with age≥ 18 years old who are willing to receive the treatment of osalmid;
  2. Patients must be diagnosed with active and measurable (symptomatic) multiple myeloma according to IMWG 2003/WHO 2008(V4) MM diagnosis criteria detailed as following:1). Positive M protein in serum and/or urine; 2). Pathologically diagnosed with multiple myeloma or found colonic plasma cells in bone marrow; 3). At least one symptom of related organ damage or tissue lesion: a. hypercalcemia: serum calcium increases 0.25mmol/L or more over upper limit of normal value(ULN) or > 2.75mmol/L; b. anemia: Hemoglobin decreases 20g/L or more over lower limit of normal value(LLN) or <100g/L;c. bone lesion: lytic bone lesion or osteoporosis accompanied with compressive fracture (confirmed with MRI、CT or PET-CT); d. others: symptomatic hyperviscosity, amyloidosis, recurrent infection (more than twice within 12 months);
  3. Eastern Cancer Organization Group (ECOG) score≤2 and expected survival>2 months;
  4. Belongs to "measurable disease": serum M protein ≥10g/L and/or 24 hour urine M protein ≥200mg;
  5. No active infectious diseases;
  6. No severe organic dysfunction (except renal function insufficiency caused by multiple myeloma), lab results must meet the following criteria (within 7 days before initiation of therapy): a. Total bilirubin ≤ 1.5*ULN (same age group); b. AST and ALT ≤ 2.5*ULN (same age group); c. Cardiac enzyme < 2*ULN (same age group); d. Normal ejection fraction confirmed in echo;
  7. Able to swallow oral medicine;
  8. Volunteer to participate into this clinical trial and the informed consents must be written by patients themselves or their direct relatives. Authorized medical attorney or direct relatives can write the informed consents if it is not good for patients' treatment when consider the severity of their disease.

Exclusion Criteria:

  1. Received anti-myeloma treatment before (not include radiotherapy, bisphosphonates or single short term steroids treatment [the dose and duration of prednisone should be no more than 40mg/d and 4 days and should discontinue this treatment within 14 days before the enrollment]);
  2. Primary or secondary plasma cell leukemia;
  3. Positive HIV tests or active infection phase of HAV, HBV and HCV; or HBV DNA copies >104/ml;AST and ALT > 2.5*ULN (same age group);
  4. Severe diseases that threaten patients with unacceptable risks; these diseases include but are not confined to unstable heart diseases, which can be defined as cardiac accidents such as MI within 6 months, NYHA stage Ⅲ-Ⅳ heart failure, uncontrolled atrial fibrillation or hypertension and myeloma requiring long term administration of steroids or immune-inhibitors;
  5. Renal failure requiring hemodialysis or peritoneal dialysis;
  6. Severe embolic or thrombotic events before therapy;
  7. Major surgery within 30 days before being enrolled;
  8. Total obstruction of biliary tract;
  9. Glaucoma;
  10. History of malignancies except multiple myeloma unless being cured for more than 3 years;
  11. Severe allergic to osalmide capsule;
  12. Gestation, lactation or disagreed pregnancy;
  13. Severe infectious diseases (uncured tuberculosis, pulmonary aspergillosis);
  14. Seizures requiring medicines, patients with dementias and other mental disorders who cannot understand or obey the protocol;
  15. Substance abuse, medical, psychological, or social conditions that may interfere with the subject's compliance in the study or assessment of the results of the study;
  16. Severe liver and kidney dysfunction;
  17. Patients who are considered unsuitable for enrollment by investigators.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03670173

Layout table for location contacts
Contact: Jumei Shi, MD PhD +86-2166306764
Contact: Weiliang Zhu, PhD +86-2150805020

Layout table for location information
China, Shanghai
Shanghai 10th People's Hospital Recruiting
Shanghai, Shanghai, China, 200072
Contact: Jumei Shi, Professor    +86-02166301604   
Sponsors and Collaborators
Shanghai 10th People's Hospital
Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Layout table for investigator information
Study Director: Jumei Shi, MD PhD Shanghai 10th People's Hospital
Principal Investigator: Weiliang Zhu, PhD Shanghai Institute of Materia Medica, Chinese Academy of Sciences


Layout table for additonal information
Responsible Party: Jumei Shi, Professor, Shanghai 10th People's Hospital Identifier: NCT03670173     History of Changes
Other Study ID Numbers: STPH-MM001
First Posted: September 13, 2018    Key Record Dates
Last Update Posted: April 9, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Jumei Shi, Shanghai 10th People's Hospital:
Multiple myeloma, Osalmid

Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases